Accord Launches OSVYRTI and JUBEREQ Biosimilars

Key Takeaways

• OSVYRTI (denosumab-desu) launched as an interchangeable biosimilar to Prolia; JUBEREQ to XGEVA.
• WAC: $1,800.41 per OSVYRTI 60 mg/mL PFS; $3,311.75 per JUBEREQ 120 mg vial.
• OSVYRTI carries a severe-hypocalcemia Boxed Warning in advanced kidney disease plus a REMS.
• Accord said both brands are Preferred on certain Cigna commercial lists as of July 1, 2026, with medical-benefit Preferred status set for September 1.

OSVYRTI and JUBEREQ at a glance

Field	Detail
Products	OSVYRTI; JUBEREQ (denosumab-desu)
Company	Accord BioPharma (Intas Pharmaceuticals)
References	Prolia (OSVYRTI); XGEVA (JUBEREQ)
Status	FDA-approved interchangeable biosimilars; U.S. commercial launch July 23, 2026
OSVYRTI WAC	$1,800.41 / 60 mg/mL PFS
JUBEREQ WAC	$3,311.75 / 120 mg vial
Safety note	OSVYRTI Boxed Warning + REMS for severe hypocalcemia in advanced CKD

What did Accord launch?

Accord said OSVYRTI covers Prolia-aligned osteoporosis and cancer-treatment bone-mass indications, while JUBEREQ covers XGEVA-aligned skeletal-related events, giant-cell tumor of bone, and refractory hypercalcemia of malignancy. Both are interchangeable under FDA biosimilar rules.

Source: Accord BioPharma's July 23 PR Newswire launch release.

Why does denosumab access matter economically?

Accord cited about 1.9 million U.S. fragility fractures yearly and Medicare Part B denosumab spending above $2 billion in 2024. The company also noted 300,000–600,000 Americans living with solid-tumor bone metastases at a given time and more than 35,000 new multiple myeloma diagnoses annually.

FDA biosimilar interchangeability basics are summarized on FDA's biosimilar and interchangeable products page.

What access supports were announced?

• Preferred status on Cigna Advantage, Performance, and Legacy Performance commercial pharmacy lists as of July 1, 2026
• Preferred on Cigna commercial medical benefit starting September 1, 2026
• AccordCares support that may reduce eligible commercially insured patient cost to as little as $0

Purple Book listings for denosumab biosimilars can be checked via FDA's Purple Book search. Interchangeability can ease pharmacy-level substitution where state law allows, but buy-and-bill oncology and rheumatology settings still turn on medical-benefit policy, ASP dynamics, and clinic inventory choices more than retail macros alone.

Clinicians starting or switching denosumab therapy should continue baseline calcium assessment, dental evaluation where indicated, and patient counseling on osteonecrosis of the jaw and atypical fracture risks that apply across the reference and biosimilar labels. Hospital and specialty pharmacy teams will also need operational readiness for OSVYRTI REMS fulfillment before high-volume conversion from Prolia.

What remains uncertain?

Net pricing after rebates, Medicare ASP dynamics, and hospital formulary uptake will determine realized savings versus WAC. REMS logistics for OSVYRTI and calcium/vitamin D monitoring remain clinical necessities. Accord's goal of 20 U.S. biosimilars by 2030 is a pipeline ambition, not a near-term supply commitment.

Related NovaPharma coverage

• FDA approves Merck oral PCSK9 drug
• FDA Activity Round Up July 2026
• Alembic Wins Tentative FDA Nod for First Generic Larotrectinib

Frequently Asked Questions

Primary Sources

1. PR Newswire: Accord — OSVYRTI and JUBEREQ launch — July 23, 2026
2. FDA: Biosimilar and interchangeable products
3. FDA: Purple Book search